Serum Institute says its vaccine candidate Covishield safe and immunogenic
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Thursday
February 02, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
THURSDAY, FEBRUARY 02, 2023
Serum Institute says its vaccine candidate Covishield safe and immunogenic

Coronavirus chronicle

Hindustan Times
01 December, 2020, 01:30 pm
Last modified: 01 December, 2020, 02:34 pm

Related News

  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • Vaccine misinformation spawns 'pure blood' movement
  • World renowned Vaccinologist Professor Dame Sarah Gilbert visits Incepta Pharma
  • Cancer vaccine hunt makes progress, finally

Serum Institute says its vaccine candidate Covishield safe and immunogenic

"All regulatory, ethical processes and guidelines were followed by the company"

Hindustan Times
01 December, 2020, 01:30 pm
Last modified: 01 December, 2020, 02:34 pm
A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines, which is working on vaccines against the coronavirus disease (Covid-19) in Pune, India, May 18, 2020. Picture taken May 18, 2020. REUTERS/Euan Rocha/File Photo/File Photo
A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines, which is working on vaccines against the coronavirus disease (Covid-19) in Pune, India, May 18, 2020. Picture taken May 18, 2020. REUTERS/Euan Rocha/File Photo/File Photo

The Serum Institute of India (SII) said on Tuesday that its vaccine candidate for the coronavirus disease (Covid-19) is "safe and immunogenic".

The company also said that the incident with one of the volunteers during clinical trials was "no way induced by the vaccine".

"All regulatory, ethical processes and guidelines were followed by the company. The principal investigator DSMB (Data and Safety Monitoring Board) and ethics committee stated it was non-related issue to vaccine trial," news agency ANI reported, quoting a statement from the SII.

The Pune-based company also said that it has sent a legal notice to a man who claimed he had developed serious side-effects in the human trials. "The legal notice was sent to safeguard the reputation of the company which is being unfairly maligned," ANI quoted SII as saying.

The man had served a legal notice on SII, claiming to have suffered a virtual neurological breakdown and impairment of cognitive functions, seeking Rs 5 crore in compensation and a halt to the trial.

The SII has collaborated with Oxford University and AstraZeneca Plc in testing Covishield, the vaccine candidate they developed.

Along with SII, the man also named Indian Council of Medical Research, one of the sponsors, and Chennai-based Sri Ramachandra Institute of Higher Education and Research, which administered the vaccine to the man.

The man, according to the notice, suffered acute encephalopathy, a disease that affects the brain, following vaccination and all tests confirmed that the setback in his health was because of the vaccine candidate.

The Drugs Controller General of India (DCGI) had deployed an institutional ethics committee at the implementation site to investigate the adverse event.

Top News / World+Biz

Serum Institute of India / Vaccine / safe / immunogenic / incident / Volunteer

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Song of the farmers as boro begins
    Song of the farmers as boro begins
  • Country's external position improves as trade deficit narrows by 21% in H1 FY23
    Country's external position improves as trade deficit narrows by 21% in H1 FY23
  • Infograph: TBS
    Remittance inflow increases 15% in January

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • Rally, scientific seminar to prevent cervical cancer held at Labaid Hospital
  • Updated Covid vaccines prevented illness from latest variants -CDC
  • Vaccine misinformation spawns 'pure blood' movement
  • World renowned Vaccinologist Professor Dame Sarah Gilbert visits Incepta Pharma
  • Cancer vaccine hunt makes progress, finally

Features

An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

22h | Panorama
Infographic: TBS

How to redirect inward remittances to formal channels

23h | Panorama
Photo: Bloomberg

How the 'madoffs of Manhattan' can unravel Gautam Adani's empire

22h | Panorama
Photo: Collected

Tips to incorporate sustainable construction

1d | Habitat

More Videos from TBS

Is Hathurusingha the most successful coach of Bangladesh?

Is Hathurusingha the most successful coach of Bangladesh?

12h | TBS SPORTS
Semiconductor, pharma should get more attention

Semiconductor, pharma should get more attention

14h | TBS Round Table
Dhali Al Mamun’s art depicts colonial impact

Dhali Al Mamun’s art depicts colonial impact

13h | TBS Stories
Jewel's humanitarian store

Jewel's humanitarian store

11h | TBS Stories

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

6
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]